Advances in genomic diagnostic methods suggest that ABC transporter resistance may be restricted to specific subsets of tumors or patient populations, and the limited clinical trial results may be due to study design flaws that do not account for differences in ABC transporter tumor expression in patients [31]. This evidence concerns the gene ABCG2 and neoplasm.